echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Haisco's innovative drug HSK36212 capsule received the "Notice of Acceptance" for clinical trial application

    Haisco's innovative drug HSK36212 capsule received the "Notice of Acceptance" for clinical trial application

    • Last Update: 2022-03-06
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On February 15, Haisco issued an announcement stating that the company has recently received the "Notice of Acceptance" for HSK36212 capsules (1mg; 5mg; 30mg) issued by the State Food and Drug Administration; the application is for domestically produced drug registration clinical trials
    .

    HSK36212 capsule is a small molecule agonist of nuclear factor-related factor pathway
    .


    It is clinically intended for the treatment of chronic kidney disease and kidney disease caused by acute kidney injury


    Preclinical studies have shown that HSK36212 capsules can inhibit the expression of genes related to renal injury and fibrosis at the molecular level in animal models of acute kidney injury and chronic kidney disease; Reducing the inflammatory response, in the detection of renal biochemical function, can increase the UPCR ratio and improve blood biochemical indicators, showing a huge potential for the treatment of renal disease


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.